Does LERCANIDIPINE Cause Bladder transitional cell carcinoma? 22 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 22 reports of Bladder transitional cell carcinoma have been filed in association with LERCANIDIPINE. This represents 0.6% of all adverse event reports for LERCANIDIPINE.
22
Reports of Bladder transitional cell carcinoma with LERCANIDIPINE
0.6%
of all LERCANIDIPINE reports
0
Deaths
22
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From LERCANIDIPINE?
Of the 22 reports, 22 (100.0%) required hospitalization.
Is Bladder transitional cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LERCANIDIPINE. However, 22 reports have been filed with the FAERS database.
What Other Side Effects Does LERCANIDIPINE Cause?
Acute kidney injury (424)
Hypotension (401)
Fall (323)
Hypertension (197)
Hyperkalaemia (176)
Drug ineffective (149)
Diarrhoea (122)
Hyponatraemia (122)
Renal impairment (120)
Oedema peripheral (114)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
ADALIMUMAB (96)
METHOTREXATE (95)
RITUXIMAB (74)
TOCILIZUMAB (68)
INFLIXIMAB (63)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
Which LERCANIDIPINE Alternatives Have Lower Bladder transitional cell carcinoma Risk?
LERCANIDIPINE vs LETAIRIS
LERCANIDIPINE vs LETERMOVIR
LERCANIDIPINE vs LETROZOLE
LERCANIDIPINE vs LETROZOLE\RIBOCICLIB
LERCANIDIPINE vs LEUCOVORIN